期刊
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
卷 137, 期 1, 页码 93-100出版社
OXFORD UNIV PRESS INC
DOI: 10.1309/AJCP59UORCYZEVQO
关键词
CD200; Chronic lymphocytic leukemia; Flow cytometry; Mantle cell lymphoma; Plasma cell myeloma
类别
资金
- Novartis
- Genzyme
- Myeloma Health
- Celgene
The membrane glycoprotein MRC OX-2 (CD200) is expressed in several lymphoid malignancies. However, the diagnostic usefulness and potential prognostic importance of CD200 expression have not been rigorously examined. We show that CD200 is uniformly expressed in chronic lymphocytic leukemia (CLL) and absent in mantle cell lymphoma (MCL). It is important to note that expression of CD200 is retained even in CLLs with immunophenotypic aberrancies, making CD200 a particularly useful marker for discrimination between these cases and MCL. CD200 is expressed in nearly all precursor B-lymphoblastic leukemias, with aberrant overexpression or underexpress ion compared with normal B-cell progenitors in 55% of cases. More than 70% of plasma cell myelomas (PCMS) expressed CD200, and loss of CD200 expression in PCM may be associated with more clinically aggressive disease. CD200 is expressed in several hematolymphoid neoplasms. Analysis of its expression has several diagnostic and potentially prognostic applications in the flow cytometric evaluation of lymphoid malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据